Clinical utility of ivabradine in cardiovascular disease management: current status

References

• Sulfi S, Timmis AD. Ivabradine – the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222–228.
   PubMed Web of Science ®Google Scholar
• Tardif JC. Ivabradine: I(f) inhibition in the management of stable angina pectoris and other cardiovascular diseases. Drugs Today (Barc). 2008;44(3):171–181.
   Web of Science ®Google Scholar
• DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399–406.
   Web of Science ®Google Scholar
• Heusch G. Pleiotropic action(s) of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol. 2008;155(7):970–971.
   Web of Science ®Google Scholar
• Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589–1601.
   Web of Science ®Google Scholar
• Guth BD, Heusch G, Seitelberger R, Ross J Jr. Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis. Circulation. 1987;75(3):661–669.
   Web of Science ®Google Scholar
• Schulz R, Rose J, Skyschally A, Heusch G. Bradycardic agent UL-FS 49 attenuates ischemic regional myocardial dysfunction and reduces infarct size in swine: comparison with the beta-blocker atenolol. J Cardiovasc Pharmacol. 1995;25(2):216–228.
   Web of Science ®Google Scholar
• Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur Heart J. 2008;29(18):2265–2275.
   Web of Science ®Google Scholar
• Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–2536.
   PubMed Web of Science ®Google Scholar
• de Silva R, Fox KM. Angina: Ivabradine for treatment of stable angina pectoris. Nat Rev Cardiol. 2009;6(5):329–330.
   Web of Science ®Google Scholar
• Tardif JC, Ponikowski P, Kahan T, ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–548.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–816.
   PubMed Web of Science ®Google Scholar
• Heusch G. A BEAUTIFUL lesson – ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur Heart J. 2009;30(19):2300–2301.
   Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337–2345.
   PubMed Web of Science ®Google Scholar
• Ceconi C, Freedman SB, Tardif JC, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146(3):408–414.
   Web of Science ®Google Scholar
• Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933–1943.
   PubMed Web of Science ®Google Scholar
• Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol. 2011;107(6):805–811.
   Web of Science ®Google Scholar
• Steg P, Lopez-de-Sa E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2(3):270–279.
   Google Scholar
• Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. Am Heart J. 2013;166(4):654–661.
   Web of Science ®Google Scholar
• McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–794.
   Web of Science ®Google Scholar
• Heusch G. Heart rate and heart failure. Not a simple relationship. Circ J. 2011;75(2):229–236.
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–885.
   PubMed Web of Science ®Google Scholar
• Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32(20):2507–2515.
   Web of Science ®Google Scholar
• Borer JS, Bohm M, Ford I, et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012;33(22):2813–2820.
   PubMed Web of Science ®Google Scholar
• Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11–22.
   Web of Science ®Google Scholar
• Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263–2270.
   PubMed Web of Science ®Google Scholar
• Ekman I, Chassany O, Komajda M, et al. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J. 2011;32(19):2395–2404.
   Web of Science ®Google Scholar
• Zuluaga MC, Guallar-Castillon P, Lopez-Garcia E, et al. Generic and disease-specific quality of life as a predictor of long-term mortality in heart failure. Eur J Heart Fail. 2010;12(12):1372–1378.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Cice G, Caminiti G, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–224.
   Web of Science ®Google Scholar
• Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–823.
   PubMed Web of Science ®Google Scholar
• Rosa GM, Ferrero S, Ghione P, Valbusa A, Brunelli C. An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure. Expert Opin Drug Metab Toxicol. 2014;10(2):279–291.
   PubMed Web of Science ®Google Scholar
• Savelieva I, Camm AJ. I f inhibition with ivabradine: electrophysiological effects and safety. Drug Saf. 2008;31(2):95–107.
   Web of Science ®Google Scholar
• Rosano GM, Vitale C, Volterrani M. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction. Adv Ther. 2010;27(4):202–210.
   Web of Science ®Google Scholar